May 2, 2024Cancer Research

Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

View Full Paper

Ask AI

Bookmark

Authors

ESErwei SongSun Yat-sen University HYHerui YaoSun Yat-sen University MSMeili SunShandong University

Discussion

Member takes

Implication

Phase 1 trial evaluates efficacy and safety of BL-M07D1 in HER2-positive breast cancer and other solid tumors, suggesting potential therapeutic benefits.

Key Points

BL-M07D1 shows encouraging efficacy in heavily pretreated HER2 expressing cancers, particularly in HER2-positive breast cancer.
Among 75 treated patients, dose-limiting toxicity occurred at 6.2 mg/kg, indicating concerns with higher dosages.
Phase 1 evaluation included 62 patients with breast cancer and other solid tumors, revealing a diverse cohort for analysis of safety and efficacy outcomes. The most common treatment-emergent adverse events included leukopenia (79%) and neutropenia (69%), indicating significant safety considerations.

Cite This Study

Song et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd2cb6db64358763d233 https://doi.org/10.1158/1538-7445.sabcs23-po2-04-03

View Full Paper

Ask AI

Bookmark

Implication

Phase 1 trial evaluates efficacy and safety of BL-M07D1 in HER2-positive breast cancer and other solid tumors, suggesting potential therapeutic benefits.

Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider